Search Results - "Muehlenweg, B"

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases by KILLEEN, S. D, ANDREWS, E. J, WANG, J. H, WU, T, SCHMALIX, W, MUEHLENWEG, B, REDMOND, H. P

    Published in British journal of cancer (29-01-2007)
    “…The urokinase plasminogen activator (u-PA) is intimately associated with tumour invasion and metastases. Surgery facilitates accelerated metastatic tumour…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Inhibition of the invasion capacity of carcinoma cells by WX‐UK1, a novel synthetic inhibitor of the urokinase‐type plasminogen activator system by Ertongur, Suna, Lang, Stephan, Mack, Brigitte, Wosikowski, Katja, Muehlenweg, Bernd, Gires, Olivier

    Published in International journal of cancer (20-07-2004)
    “…The overall survival rate of patients suffering from carcinomas has remained poor and nearly unchanged over the last decades. This is mainly due to the…”
    Get full text
    Journal Article
  4. 4

    High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread by Sato, Sumito, Kopitz, Charlotte, Schmalix, Wolfgang A, Muehlenweg, Bernd, Kessler, Horst, Schmitt, Manfred, Krüger, Achim, Magdolen, Viktor

    Published in FEBS letters (25-09-2002)
    “…Urokinase-type plasminogen activator (uPA) binds with high affinity to its specific cell surface receptor (uPAR) (CD87) via a well-defined sequence within the…”
    Get full text
    Journal Article
  5. 5

    The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin by Coles, M, Diercks, T, Muehlenweg, B, Bartsch, S, Zölzer, V, Tschesche, H, Kessler, H

    Published in Journal of molecular biology (28-05-1999)
    “…Human neutrophil gelatinase-associated lipocalin (HNGAL) is a member of the lipocalin family of extracellular proteins that function as transporters of small,…”
    Get full text
    Journal Article
  6. 6

    Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours by Muehlenweg, B, Sperl, S, Magdolen, V, Schmitt, M, Harbeck, N

    Published in Expert opinion on biological therapy (01-07-2001)
    “…There is abundant evidence that the plasminogen activator (PA) system with its key components uPA (urokinase-type plasminogen activator), its cell surface…”
    Get more information
    Journal Article
  7. 7

    Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy by Seliger, Barbara, Menig, Matthias, Lichtenfels, Rudolf, Atkins, Derek, Bukur, Jürgen, Halder, Thomas M., Kersten, Michael, Harder, Alois, Ackermann, Angelika, Beck, Joachim, Muehlenweg, Bernd, Brenner, Walburgis, Melchior, Sebastian, Kellner, Roland, Lottspeich, Friedrich

    Published in Proteomics (Weinheim) (01-06-2003)
    “…Renal cell carcinoma (RCC) represents the most common malignant tumor in the kidney and is resistant to conventional therapies. The diagnosis of RCC is often…”
    Get full text
    Journal Article Conference Proceeding
  8. 8
  9. 9
  10. 10

    Induction of tumor cell death by high hydrostatic pressure as a novel supporting technique in orthopedic surgery by Diehl, Peter, Schmitt, Manfred, Blümelhuber, Gerrit, Frey, Benjamin, Van Laak, Susanne, Fischer, Steffen, Muehlenweg, Bernd, Meyer-Pittroff, Roland, Gollwitzer, Hans, Mittelmeier, Wolfram

    Published in Oncology reports (01-11-2003)
    “…As vegetative forms of microorganisms are impaired by high hydrostatic pressure (HHP) in the range of 400-600 MPa, the non-thermal inactivation of vegetative…”
    Get more information
    Journal Article
  11. 11

    A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site by Muehlenweg, B, Assfalg-Machleidt, I, Parrado, S G, Bürgle, M, Creutzburg, S, Schmitt, M, Auerswald, E A, Machleidt, W, Magdolen, V

    Published in The Journal of biological chemistry (27-10-2000)
    “…Cancer invasion and metastasis is a process requiring a coordinated series of (anti-)adhesive, migratory, and pericellular proteolytic events involving various…”
    Get full text
    Journal Article
  12. 12

    Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis by Diehl, Peter, Hantke, Bernd, Hennig, Michael, Tschesche, Harald, Mittelmeier, Wolfram, Schmitt, Manfred, Muehlenweg, Bernd

    “…Matrix metalloproteinase 13 (MMP-13), urokinase type plasminogen activator (uPA), and plasminogen activator inhibitor type-1 (PAI-1) have been reported to be…”
    Get more information
    Journal Article
  13. 13
  14. 14

    Interaction of plasminogen activator inhibitor type‐1 (PAI‐1) with vitronectin: Characterization of different PAI‐1 mutants by Arroyo De Prada, Nuria, Schroeck, Florian, Sinner, Eva‐Kathrin, Muehlenweg, Bernd, Twellmeyer, Jens, Sperl, Stefan, Wilhelm, Olaf G., Schmitt, Manfred, Magdolen, Viktor

    Published in European journal of biochemistry (01-01-2002)
    “…The serpin plasminogen activator inhibitor type 1 (PAI‐1) plays an important role in physiological processes such as thrombolysis and fibrinolysis, as well as…”
    Get full text
    Journal Article
  15. 15